This proposal tests the hypothesis that naturally-occurring and synthetic organoselenium compounds (SeC) modify growth of human prostate cancer (CaP) cells by targeting redox sensitive signal proteins and transcription factors thereby regulating proliferative and/or apoptotic responses. Inhibition of cell proliferation and induction of apoptosis are major cancer preventive activities of SeC. Preliminary studies document selective growth inhibitory effects of SeCs utilizing phenotypically similar androgen-responsive (AR+) and - non-responsive (AR-) human LNCaP cells. Proteomic studies reveal that the form of Se and the cell's hormonal status play critical roles in growth inhibition. To test our hypothesis we formulated 3 specific aims.
Aim 1 characterizes antiproliferative mechanisms of SeC in AR+ and AR- cells. Studies will compare time and dose-response effects of SeC on cytometric measurements, cell proliferation, apoptotic_processes, and intracellular redox environment. Proteomic analyses will examine expression profiles of selected redox sensitive signal and transcription factors.
Aim 2 identifies sites and characterizes the type of interaction between SeC and selected redox signal proteins. Purified or recombinant proteins selected from prolifiterative and apoptotic pathways will be studied to identify occurrences of covalent intra- and intermolecular -S-S- or S- Se conjugates. Immunoprecipitations of similar signal proteins from control and SeC-treated AR+ and AR- cells will be studied. HPLC separation of proteolytic digests followed by MALDI-TOF MS analyses will locate sites of protein modification.
In Aim 3, nude mice implanted with AR+ and AR- cells and TRAMP mice are fed diets containing low and high levels of SeC (including selenized yeast). Global expression profiles of redox-sensitive signal proteins as defined in Aim 1 will be determined relative to dietary SeC in these models. Completion of this study will define the molecular targets of SeC at the proteomic level and will identify in AR+ and AR- human prostate cancer cells distinct physiological responses necessary for chemopreventive action. Also, this study aims to determine whether the molecular environment in which Se resides mediates redox sensitive signal and/or transcription factors that regulate proliferative and/or apoptotic processes in CaP. Molecular targets identified in this study will provide relevant biomarkers useful for the on-going SELECT Study that examines selenomethionine for prevention of CaP. Our proposal determines the role of various forms of selenium (natural and synthetic) on protein targets implicated in development of human prostate cancer. The long-term goal of our reseach is to design appropriate dietary strategies for prevention of prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA111842-05
Application #
7669081
Study Section
Chemo/Dietary Prevention Study Section (CDP)
Program Officer
Kim, Young S
Project Start
2006-08-04
Project End
2011-07-31
Budget Start
2009-08-01
Budget End
2011-07-31
Support Year
5
Fiscal Year
2009
Total Cost
$290,071
Indirect Cost
Name
New York Medical College
Department
Biochemistry
Type
Schools of Medicine
DUNS #
041907486
City
Valhalla
State
NY
Country
United States
Zip Code
10595
Kim, Eunah; Bisson, William H; Löhr, Christiane V et al. (2016) Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors. Curr Top Med Chem 16:714-31
Kang, Y; Nian, H; Rajendran, P et al. (2014) HDAC8 and STAT3 repress BMF gene activity in colon cancer cells. Cell Death Dis 5:e1476
Sinha, Indu; Allen, Joshua E; Pinto, John T et al. (2014) Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia. Cancer Med 3:252-64
Pinto, John T; Krasnikov, Boris F; Alcutt, Steven et al. (2014) Kynurenine aminotransferase III and glutamine transaminase L are identical enzymes that have cysteine S-conjugate ?-lyase activity and can transaminate L-selenomethionine. J Biol Chem 289:30950-61
Bridges, Christy C; Krasnikov, Boris F; Joshee, Lucy et al. (2012) New insights into the metabolism of organomercury compounds: mercury-containing cysteine S-conjugates are substrates of human glutamine transaminase K and potent inactivators of cystathionine ?-lyase. Arch Biochem Biophys 517:20-9
Tsikas, Dimitrios; Evans, Christopher E; Denton, Travis T et al. (2012) Stable isotope gas chromatography-tandem mass spectrometry determination of aminoethylcysteine ketimine decarboxylated dimer in biological samples. Anal Biochem 430:4-15
Facompre, Nicole D; Sinha, Indu; El-Bayoumy, Karam et al. (2012) Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1,4-phenylenebis(methylene)selenocyanate in human prostate cancer cells. Int J Cancer 131:2134-42
Sinha, Indu; Null, Kevin; Wolter, William et al. (2012) Methylseleninic acid downregulates hypoxia-inducible factor-1? in invasive prostate cancer. Int J Cancer 130:1430-9
Cooper, Arthur Jl; Pinto, John T; Callery, Patrick S (2011) Reversible and irreversible protein glutathionylation: biological and clinical aspects. Expert Opin Drug Metab Toxicol 7:891-910
Pinto, John T; Lee, Jeong-In; Sinha, Raghu et al. (2011) Chemopreventive mechanisms of ýý-keto acid metabolites of naturally occurring organoselenium compounds. Amino Acids 41:29-41

Showing the most recent 10 out of 23 publications